Open interest in HSBIO futures surge 245% to 883 in October

Monthly,how er, performance dropped 16.2% in the same period.

Hang Seng Biotech Index (HSBIO) recorded 883 open interest in futures on 30 October, 245% higher than end-2025 tally, according to Hang Seng Biotech Monthly.

The average daily volume of HSBIO futures was 373 contracts in the first ten months, higher than the previous year’s 205 contracts.

HSBIO’s performance dropped 16.2%, lower than Hang Seng Composite Index’s (HSCI) -7.2% month on month (MoM). Hang Seng HK-US Biotech Index (HSUSB) is the best performer in October, posting a monthly decline of 11.3%.

Across HSBIO’s subsectors, medical devices & supplies recorded the only growth in October, tallying 7.8%.

Medicine Distribution is down 5.7%, alongside Pharma & Biotech Contract Services (-11.9%) and Biotechnology (-13.4%). Pharmaceuticals dropped the most, at 20.8%.

Across 30 HSBIO constituents, monthly price changes ranged from 48.4% to 9%—25 down, two flat, and three up.

Sinopharm topped price increases by 9%, followed by JD Health (6%) and Chinares Pharma (4%). DualityBio dropped the most at 48%.

The top five performing constituents in HSBIO’s key subsectors showed 6.1% index weightings, whilst the bottom five constituents totalled 11.3% index weightings.